These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
388 related articles for article (PubMed ID: 38607035)
1. Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy. Sun C; Serra C; Kalicharan BH; Harding J; Rao M Cells; 2024 Mar; 13(7):. PubMed ID: 38607035 [TBL] [Abstract][Full Text] [Related]
2. iMyoblasts for ex vivo and in vivo investigations of human myogenesis and disease modeling. Guo D; Daman K; Chen JJ; Shi MJ; Yan J; Matijasevic Z; Rickard AM; Bennett MH; Kiselyov A; Zhou H; Bang AG; Wagner KR; Maehr R; King OD; Hayward LJ; Emerson CP Elife; 2022 Jan; 11():. PubMed ID: 35076017 [TBL] [Abstract][Full Text] [Related]
3. Mesodermal iPSC-derived progenitor cells functionally regenerate cardiac and skeletal muscle. Quattrocelli M; Swinnen M; Giacomazzi G; Camps J; Barthélemy I; Ceccarelli G; Caluwé E; Grosemans H; Thorrez L; Pelizzo G; Muijtjens M; Verfaillie CM; Blot S; Janssens S; Sampaolesi M J Clin Invest; 2015 Dec; 125(12):4463-82. PubMed ID: 26571398 [TBL] [Abstract][Full Text] [Related]
4. Generation of human myogenic progenitors from pluripotent stem cells for in vivo regeneration. Kim H; Perlingeiro RCR Cell Mol Life Sci; 2022 Jul; 79(8):406. PubMed ID: 35802202 [TBL] [Abstract][Full Text] [Related]
7. Myogenic differentiation of muscular dystrophy-specific induced pluripotent stem cells for use in drug discovery. Abujarour R; Bennett M; Valamehr B; Lee TT; Robinson M; Robbins D; Le T; Lai K; Flynn P Stem Cells Transl Med; 2014 Feb; 3(2):149-60. PubMed ID: 24396035 [TBL] [Abstract][Full Text] [Related]
14. Stem cell therapies to treat muscular dystrophy: progress to date. Meregalli M; Farini A; Parolini D; Maciotta S; Torrente Y BioDrugs; 2010 Aug; 24(4):237-47. PubMed ID: 20623990 [TBL] [Abstract][Full Text] [Related]
15. Do Induced Pluripotent Stem Cell Characteristics Correlate with Efficient In Vitro Smooth Muscle Cell Differentiation? A Comparison of Three Patient-Derived Induced Pluripotent Stem Cell Lines. Zhou Y; Kang G; Wen Y; Briggs M; Sebastiano V; Pederson R; Chen B Stem Cells Dev; 2018 Oct; 27(20):1438-1448. PubMed ID: 30153084 [TBL] [Abstract][Full Text] [Related]
16. Perspectives on hiPSC-Derived Muscle Cells as Drug Discovery Models for Muscular Dystrophies. Abati E; Sclarandi E; Comi GP; Parente V; Corti S Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502539 [TBL] [Abstract][Full Text] [Related]
17. Stem Cell Differentiation Toward the Myogenic Lineage for Muscle Tissue Regeneration: A Focus on Muscular Dystrophy. Ostrovidov S; Shi X; Sadeghian RB; Salehi S; Fujie T; Bae H; Ramalingam M; Khademhosseini A Stem Cell Rev Rep; 2015 Dec; 11(6):866-84. PubMed ID: 26323256 [TBL] [Abstract][Full Text] [Related]
18. Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Jha BS; Farnoodian M; Bharti K Stem Cells Transl Med; 2021 Feb; 10(2):198-208. PubMed ID: 32946199 [TBL] [Abstract][Full Text] [Related]
19. Autologous Induced Pluripotent Stem Cell-Based Cell Therapies: Promise, Progress, and Challenges. Madrid M; Sumen C; Aivio S; Saklayen N Curr Protoc; 2021 Mar; 1(3):e88. PubMed ID: 33725407 [TBL] [Abstract][Full Text] [Related]
20. Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation. Paes BCMF; Moço PD; Pereira CG; Porto GS; de Sousa Russo EM; Reis LCJ; Covas DT; Picanço-Castro V Cell Biol Toxicol; 2017 Jun; 33(3):233-250. PubMed ID: 28039590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]